Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alpharma’s new Kadian dose gets approvable status
Kadian is Alpharma’s branded sustained release morphine sulfate product and is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages. The company plans to launch the new
Kadian is Alpharma’s branded sustained release morphine sulfate product and is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages. The company plans to launch the new
The biotechnology company reviewed both this study and additional preclinical data conducted with outside collaborators, before concluding the drug was ready for further investigation. CTCE-9908 is designed to
Following notice given in December 2004 that the FDA would not approve the product for release after the company’s first submission, Cellegy has provided a written response containing
The research collaboration, which began in August 2002 aims to identify specific small molecule drug candidates against a ligase target that controls the spreading of cancer cells through
The multi-center study is designed to evaluate clinical safety of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs. The trial, cleared
The trial is a double-blind, placebo- controlled, multinational clinical study using patients with advanced chronic heart failure. Vasogen has enrolled over 2,000 patients at 173 clinical sites in
In collaboration with Dr Scott Plevy, a clinical gastroenterologist at the University of Pittsburgh Medical Center, SP304 was shown to be effective in preliminary experiments conducted in an
The gene therapy company, in collaboration with the Institute of Ophthalmology in London, has presented data showing that two versions of the RetinoStat product are efficacious in an
Requip (ropinirole HCl) is a second-generation dopamine agonist that directly stimulates dopamine receptors in the brain. Although its exact cause is unknown, researchers believe that the underlying cause
The small business innovative research (SBIR) grant will go towards the development of a vaccine to combat helicobacter pylori (H. pylori), a major cause of gastritis and gastroduodenal